Protagonist Therapeutics
PTGX
PTGX
311 hedge funds and large institutions have $6.18B invested in Protagonist Therapeutics in 2025 Q4 according to their latest regulatory filings, with 80 funds opening new positions, 97 increasing their positions, 103 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
14% more funds holding
Funds holding: 274 → 311 (+37)
0.49% less ownership
Funds ownership: 113.62% → 113.13% (-0.49%)
6% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 103
Holders
311
Holding in Top 10
13
Calls
$85.2M
Puts
$4.57M
Top Buyers
| 1 | +$127M | |
| 2 | +$103M | |
| 3 | +$94.7M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$72.7M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$71.5M |
Top Sellers
| 1 | -$170M | |
| 2 | -$114M | |
| 3 | -$66.8M | |
| 4 |
RI
RTW Investments
New York
|
-$57.1M |
| 5 |
CC
Commodore Capital
New York
|
-$47.1M |
